Avid preps to kick-off $30-40m manufacturing expansion

Avid Bioservices says it is undertaking pre-engineering and design work on a facility aimed at supporting demand for biomanufacturing services.

Dan Stanton, Managing editor

July 3, 2020

2 Min Read
Avid preps to kick-off $30-40m manufacturing expansion
Image: iStock/artisteer

Though no date has been set, Avid Bioservices says it is undertaking pre-engineering and design work on a long-awaited facility aimed at supporting soaring demand for biomanufacturing services.

For a while, contract development and manufacturing organization (CDMO) Avid Bioservices has been pushing to build out its Myford, California production facility to prepare for continued high demand from the biologics sector.

But on its latest financial call, management said the firm is readying itself for the expansion in preparation for growth opportunities ahead.


Image: iStock/artisteer

“While specific kick-off date has not been set for this expansion, we recognize that construction may take between 18 months and 24 months to complete. For that reason, we are undertaking the pre-engineering, design, and permitting work required to allow us to break ground on this project at the appropriate time,” Richard Hancock, interim president and CEO, told stakeholders.

“Our customer relationships are strong and forecasted demand is growing. Combined with our expanded business development activity, which we expect to generate an increasing number of projects from both existing and new customers, we believe that we are on a path to significantly increased capacity utilization. Accordingly, we are readying to kick-off an expansion that will allow us to meet the increasing demand of our ever-growing customer list. This concludes my prepared remarks for today.”

CFO Daniel Hart added that these initial steps require a low outlay of capital expenditure but does allow the CDMO to pull the trigger on construction at any moment.

“Once we find the right time and move forward toward building out, at that time, we’ll look at any financing options that we feel are appropriate when the time presents itself.”

However, Timothy Compton, chief commercial officer, responded to a question saying that “the overall build-out would be somewhere around $30 million to $40 million all-in” and would take 18 to 24 months to be completed.

For the full fiscal year 2020, ending April 30, Avid reported revenues of $59.7 million, up 11% on the previous year. The fourth quarter also saw the firm achieve a record backlog of $65 million.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like